
- compound 186: 7-(2-methylpyrid-4-yl)-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 196: 8-chloro-7-(pyrid-4-yl)-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 199: 8-chloro-7-(2-chloropyrid-3-yl)-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 209: 7-{2-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 232: *N*-{2-[4-oxo-5-(2,2,2-trifluoroethyl)-4,5-dihydro-2*H*-pyrazolo[4,3-*c*]quinolin-7-yl]phenyl}methanesulfonamide;
- compound 248: 7-[2-(dimethylamino)pyrid-3-yl]-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 251: 7-[2-(pyrrolidin-1-yl)pyrid-3-yl]-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 257: 7-[2-(diethylamino)pyrid-3-yl]-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;
- compound 273: 7-[2-(4-fluoropiperidin-1-yl)pyrid-3-yl]-5-(2,2,2-trifluoroethyl)-1,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-one;

in the form of the base or of an acid-addition salt, and also in hydrate form.


~~7. Compound of formula (III):~~



~~(III)~~

~~in which R3 is as defined in Claim 1 and Hal represents a halogen atom; in the form of the base or of an acid-addition salt, and also in hydrate form.~~


~~8. Compound of formula (IV):~~



~~(IV)~~

~~in which R3 is as defined in Claim 1 and Hal represents a halogen atom; in the form of the base or of an acid-addition salt, and also in hydrate form.~~


~~9~~7. Compound of formula (V):



(V)

in which R3 is as defined in Claim 1 and Hal represents a halogen atom; in the form of the base or of an acid-addition salt, and also in hydrate form.


~~10~~8. Compound of formula (VI):



(VI)

in which R3 is as defined in Claim 1, Hal represents a halogen atom and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.

~~11~~9. Compound of formula (VII):




(VII)

(VII)

in which R1 and R3 are as defined in Claim 1, Hal represents a halogen atom and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.


~~12~~10. Compound of formula (VIII):



(VIII)

in which R1, R2 and R3 are as defined in Claim 1 and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.


~~13~~11. Compound of formula (IX):



(IX)

in which R2 is as defined in Claim 1, R3 represents –H, a halogen, -(C1-C6)alkyl, a cyano group or $–CONH_2$ and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.


~~14. Compound of formula (XIII):~~



~~(XIII)~~

~~in which R1 is as defined in Claim 1, Hal represents a halogen atom and R3 represents H, a halogen chosen from chlorine, bromine and iodine, -(C1-C6)alkyl, a cyano group, $-CO_2H$ or $-CONH_2$; in the form of the base or of an acid-addition salt, and also in hydrate form.~~


~~15~~12. Compound of formula (XIV):



(XIV)

in which R1 and R3 are as defined in Claim 1 and Hal represents a halogen atom; in the form of the base or of an acid-addition salt, and also in hydrate form.


~~16. Compound of formula (XVII):~~



~~(XVII)~~

~~in which R3 is as defined in Claim 1, Hal represents a halogen atom and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.~~


~~17. Compound of formula (XVIII):~~



~~(XVIII)~~


~~in which R1 and R3 are as defined in Claim 1, Hal represents a halogen atom and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.~~

~~18~~13. Compound of formula (XIX):



in which R1 and R3 are as defined in Claim 1 and R represents a hydrogen atom or both the groups R are carbon atoms bonded together and optionally substituted with one or more groups (C1-C4) alkyl; in the form of the base or of an acid-addition salt, and also in hydrate form.

~~19~~14. Compound of formula (XX):



in which R1 and R3 are as defined in Claim 1 and R represents a hydrogen atom or both the groups R are carbon atoms bonded together and optionally substituted with one or more groups (C1-C4) alkyl and PG represents a protecting group; in the form of the base or of an acid-addition salt, and also in hydrate form.

~~20~~15. Medicament, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 6, or an addition salt of this compound with a pharmaceutically acceptable acid.

~~21~~16. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 6, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

~~22~~17. Compound of general formula (I) as defined in any one of Claims 1 to 6, for its use as a medicament.

~~23~~18. Compound of general formula (I) as defined in any one of Claims 1 to 6, for the preparation of a medicament for preventing or treating pulmonary and hepatic fibrosis; pathologies involving a reactivation of angiogenesis, such as diabetic retinopathy, age-related macular degeneration (ARMD) and psoriasis; any carcinoma with a substantial degree of vascularization, such as lung, breast, prostate, oesophageal, pancreatic, liver, colon or kidney carcinoma or any carcinoma inducing metastases, such as colon, breast, liver or stomach carcinomas, and melanomas; solid tumours, such as pancreatic, breast, prostate, colon or kidney tumours, neuroblastomas and Kaposi's sarcoma; hepatocarcinomas; cholangiocarcinoma; malignant mesothelioma; pancreatic cancer; haemoangioma; endometriosis; arthritis and in particular rheumatoid arthritis; obesity; autoimmune diseases; microsporidiosis.

~~24~~19. Use of a compound of formula (I) according to any one of Claims 1 to 6, for the preparation of a medicament for preventing or treating pulmonary and hepatic fibrosis; pathologies involving a reactivation of angiogenesis, such as diabetic retinopathy, age-

related macular degeneration (ARMD) and psoriasis; any carcinoma with a substantial degree of vascularization, such as lung, breast, prostate, oesophageal, pancreatic, liver, colon or kidney carcinoma or any carcinoma inducing metastases, such as colon, breast, liver or stomach carcinomas, and melanomas; solid tumours, such as pancreatic, breast, prostate, colon or kidney tumours, neuroblastomas and Kaposi's sarcoma; hepatocarcinomas; cholangiocarcinoma; malignant mesothelioma; pancreatic cancer; haemoangioma; endometriosis; arthritis and in particular rheumatoid arthritis; obesity; autoimmune diseases; microsporidiosis.

~~25~~20. Use of a compound of formula (I) according to any one of Claims 1 to 6, in monotherapy or in combination with radiotherapy or chemotherapy.